Advanced Proteome Therapeutics (STU:0E81) ROC %: -602.20% (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics ROC %?

Advanced Proteome Therapeutics STU:0E81 ROC % is -602.20% as of Apr. 2023.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Advanced Proteome Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Apr. 2023 was -602.20%.

As of today (2026-07-31), Advanced Proteome Therapeutics's WACC % is 0.00%. Advanced Proteome Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). Advanced Proteome Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Advanced Proteome Therapeutics  (STU:0E81) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Advanced Proteome Therapeutics's WACC % is 0.00%. Advanced Proteome Therapeutics's ROC % is 0.00% (calculated using TTM income statement data). Advanced Proteome Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Advanced Proteome Therapeutics ROC % Related Terms

Advanced Proteome Therapeutics ROC % Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics ROC % Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,064.41 -1,388.24 -501.01 -420.66 -746.25

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -274.61 -378.40 -892.70 -791.08 -602.20

Advanced Proteome Therapeutics ROC % Calculation

Advanced Proteome Therapeutics's annualized Return on Capital (ROC %) for the fiscal year that ended in Jul. 2022 is calculated as:

ROC % (A: Jul. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jul. 2021 ) + Invested Capital (A: Jul. 2022 ))/ count )
=-0.944 * ( 1 - 0% )/( (0.135 + 0.118)/ 2 )
=-0.944/0.1265
=-746.25 %

where

Invested Capital(A: Jul. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.76 - 0.716 - ( 0.695 - max(0, 0.845 - 0.754+0.695))
=0.135

Invested Capital(A: Jul. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.625 - 1.121 - ( 0.535 - max(0, 1.224 - 0.61+0.535))
=0.118

Advanced Proteome Therapeutics's annualized Return on Capital (ROC %) for the quarter that ended in Apr. 2023 is calculated as:

ROC % (Q: Apr. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2023 ) + Invested Capital (Q: Apr. 2023 ))/ count )
=-0.548 * ( 1 - 0% )/( (0.154 + 0.028)/ 2 )
=-0.548/0.091
=-602.20 %

where

Invested Capital(Q: Jan. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.303 - 0.99 - ( 0.271 - max(0, 1.131 - 0.29+0.271))
=0.154

Invested Capital(Q: Apr. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.057 - 0.049 - ( 0.036 - max(0, 0.077 - 0.057+0.036))
=0.028

Note: The Operating Income data used here is four times the quarterly (Apr. 2023) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -602.20% mean?
Advanced Proteome Therapeutics (STU:0E81) has a ROC % of -602.20% as of Apr. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' ROC % too high?
Advanced Proteome Therapeutics' current ROC % is -602.20%.
How does Advanced Proteome Therapeutics' ROC % compare to VRTX and REGN?
Advanced Proteome Therapeutics' ROC % of -602.20% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current ROC % is -602.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current ROC % of -602.20%. The current ROC % is -602.20%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current ROC % is -602.20% as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.